Search

Luteinizing hormone

Streptococcus pneumoniae type 17f capsular polysaccharide antigen

It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

Enalaprilat

Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. … Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.

Danaparoid

While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan.

Glutathione

A tripeptide with many roles in cells. … It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

Nitrous acid

It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. … Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning.

Lasmiditan

[sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. … Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.

Topiroxostat

While [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens … Approved for therapeutic use in Japan since 2013, topiroxostat is marketed under the name Topiloric and Uriadec and is orally administered twice daily.

Digitoxin

(From Martindale, The Extra Pharmacopoeia, 30th ed, p665) … A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting.

Olipudase alfa

[A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022. … [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]